Rocket Lab (RKLB)

Aeroespacial y defensa

Rocket Lab combines a launch business with market-leading flight heritage among small rockets (Electron, 75 successful missions) and a space systems division built through acquisitions, with revenue growing strongly but operating income still negative. The market price bakes in a considerable premium for the Neutron optionality, which does not yet generate revenue. No margin of safety: the price already discounts a demanding scenario.

Moat Compounder estimates the intrinsic value of Rocket Lab (RKLB) at $14 per share on a five-year horizon. With the stock at $64.39 at 2026-08-28 close, the expected total return is -26.4% per year: overvalued. The analysis draws on 10-K FY2025 and 8-K (2Q 2026). Analysis dated 2026-08-10.

Price
$64.39
at 2026-08-28 close
Intrinsic value (5y, base)
$14
Total annual return (5y)
-26.4%
Status (nominal)
Overvalued
Margin of safety
No margin

The essentials

  • TTM revenue of US$0.769 billion (+52.5% year over year), with a contracted backlog of US$2.36 billion at 2Q 2026 (+137% year over year) anchoring forward growth.
  • Operating income still negative (-29.1% margin in the TTM), but improving steadily from -72.7% in 2023 as the company gains scale.
  • Neutron, the medium-lift rocket that would enable the jump in revenue per launch, suffered a Stage 1 tank pressure test failure in January 2026 and its first flight keeps slipping.
Source10-K FY2025Dec 31, 2025·8-K (2Q 2026)Aug 10, 2026·DEF 14A 2026 (proxy)Apr 6, 2026
Health: Fragile
Price$64at 2026-08-28 closeMarket Cap$40.5 bnEnterprise Value$38.2 bnNet cash$2.3 bnEV/EBIT (at 5 years)103.0x

Intrinsic value — two valuation methods

No margin of safety
Pricevalue today
$64
DCFvalue today
Not applicableThe initial flow (TTM) is negative: -US$0.233 billion of owner earnings, depressed by stock-based compensation (10.6% of revenue) and by capex well above depreciation (LC-3, Neutron manufacturing expansion and space systems). A negative flow capitalized at a positive growth rate does not converge to a meaningful value, so the present-value discount does not apply. The valuation runs on the sum of the parts projected to year 5, when consolidated operating income crosses into positive territory in the base case.
Multiplesvalue today
$11
-82.7% vs price

The value today by multiples ($11) is below the market price ($64). The present-value lens does not apply to this company, so the contrast between methods is unavailable.

Pillars of the analysis

The verdict — today vs 5 years

Today — expensive, no margin of safety: at $64 trades ~477.3% above its value discounted to today (~$11); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$7.

Thesis

The business

A launch business with real flight heritage (75 successful missions) and a components division built through acquisitions, with revenue growing strongly (+52.5% in the TTM) but operating income still negative. The US$2.36 billion backlog supports the growth projection with already-booked revenue, not extrapolated revenue.

The valuation

Valued as a sum of the parts: Space Systems at ~16x and Launch Services at ~19x year-5 operating income, a blended multiple of ~17.4x, within the 15-22x band of the aerospace archetype. The present-value discount does not apply because today's owner cash flow is negative.

The margin of safety

No margin of safety: the price already discounts a demanding scenario. At the market price (US$64.39) the implied return is -26% annually over five years — the base case Overvalued.

What to watch

The key disconfirmer is whether Neutron achieves its first commercial flight and qualifies for the medium-lift launch market; without that jump in revenue per launch, consolidated operating income could take longer than five years to cross into positive territory, and the current price — which capitalizes close to 50 times TTM revenue — would be left without fundamental support.

Educational / informational. Does not constitute investment advice.